VEGF165 plasmid DNA

VEGF165 plasmid DNA is a gene therapy candidate developed by the Ottawa Heart Institute Research Corporation for the treatment of severe coronary artery disease (CAD). The therapy consists of a plasmid vector encoding the 165-amino acid isoform of human vascular endothelial growth factor (VEGF-165). When injected directly into the heart muscle (intramyocardial administration), the plasmid is taken up by myocardial cells, leading to the local expression and secretion of the VEGF-165 protein. This protein acts as a potent mitogen for endothelial cells, stimulating angiogenesis—the formation of new collateral blood vessels—to improve myocardial perfusion in areas of the heart that are not amenable to traditional revascularization techniques like bypass surgery. In the EMAT clinical trial, this gene therapy was evaluated in combination with L-arginine supplementation to determine if improving endothelial function could enhance the efficacy of the angiogenic treatment.

Other names

VEGF-165 gene therapyVEGF165 gene therapyVEGF 165 gene therapyplasmid VEGF-165intramyocardial VEGF angiogenesisvascular endothelial growth factor 165 plasmid DNA